SCHEMBL6407392

SCHEMBL6407392

CCN(CC)C(=O)CCc1c[nH]c2c1C(=O)CCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
LMNA P02545 3/20 0.38
PTK2 Q05397 1/20 0.33
PARP1 P09874 1/20 0.33
PTPN1 P18031 1/20 0.33
BRD4 O60885 1/20 0.33
RECQL P46063 1/20 0.32
TSHR P16473 2/20 0.32
NPC1 O15118 1/20 0.32
GAA P10253 1/20 0.32
ALOX15 P16050 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
AURKA O14965 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KMT2A Q03164 3/20 0.30
MEN1 O00255 2/20 0.30
NPSR1 Q6W5P4 1/20 0.30
CDK4 P11802 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6412628 0.87 PTK2 (0.35) ALDH1A1LMNAPTK2BRD4TSHR
SCHEMBL6692185 0.84 CDK4 (0.33) LMNAPTK2TSHRNPC1GAA
SCHEMBL3802492 0.82 GAA (0.46) ALDH1A1LMNAPTK2BRD4TSHR
SCHEMBL3797505 0.81 GPR17 (0.40) LMNAPTK2PARP1TSHRNPC1
SCHEMBL5409905 0.80 ALDH1A1 (0.39) ALDH1A1LMNAPTPN1RECQLAURKA
SCHEMBL7989412 0.80 MPO (0.39) LMNAPTK2BRD4TSHRNPC1
SCHEMBL6695442 0.78 GPR17 (0.40) LMNAPTK2PARP1TSHRNPC1
SCHEMBL5413673 0.75 KMT2A (0.50) ALDH1A1LMNANPC1GAASMN1; SMN2
SCHEMBL5410145 0.74 GLA (0.42) ALDH1A1LMNAPARP1GAAHTT
SCHEMBL24611538 0.74 CYP1A2 (0.46) ALDH1A1LMNATSHRRAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 US disclosed
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 US disclosed
US-6531502-B1 Antitumor SUGEN, INC. 2003-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase DMPK, MAP4K3, MAP3K20 ALDH1A1 2196/4885LMNA 3031/4885PTK2 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.